Navigation Links
Robert W. Lee, Ph.D. Joins Particle Sciences as Vice President of Pharmaceutical Development
Date:4/28/2008

BETHLEHEM, Pa., April 28 /PRNewswire/ -- Particle Sciences, Inc. today announced the appointment of Robert W. Lee, Ph.D. to the position of Vice President, Pharmaceutical Development.

Dr. Lee joins Particle Sciences following more than 17 years experience in pharmaceutical research and development of both therapeutic drugs and diagnostic imaging agents. Most recently, he served Novavax, Inc. as Vice President of Pharmaceutical Development. Prior to that, Dr. Lee held senior management positions at Lyotropic Therapeutics, Inc. and IMCOR Pharmaceutical Co. Dr. Lee is currently serving as a scientific advisor for NanoScan Imaging, LLC, and Savara Pharmaceutical.

From 1990 to 2002, Dr. Lee held various R&D positions within Sterling Winthrop Pharmaceuticals Research Division, NanoSystems, and elan Drug Delivery, Inc. His areas of expertise include Preformulation, drug delivery, formulation development, analytical sciences, sterile manufacturing, and technology evaluation and development. Dr. Lee was one of the founding members of NanoSystems, a drug delivery company focused on the formulation of water-insoluble drugs. He maintains strong academic ties, including an appointment as Adjunct Associate Professor of Pharmaceutical Chemistry at the University of Kansas in 1992, and serving as a reviewer for both the International Journal of Pharmaceutics and Journal of Pharmaceutical Sciences.

Dr. Mitchnick comments that "Robert brings a wealth of experience to the Particle Sciences team. His background fits perfectly with our continued focus on advanced delivery systems. Particle Sciences typically deals with difficult to solubilize API's and nanotechnology based systems. Rob has deep experience in these areas as well as in clinical trial manufacturing, another area in which Particle sciences is expanding."

Dr. Lee received a Ph.D. in Physical Bioorganic Chemistry under the direction of Professor Thomas C. Bruice from the University of California, Santa Barbara and B.Sc.'s in both Chemistry and Biology from the University of Washington. He is the author or co-author of 11 patents, 14 provisional and PCT patent applications, nine research articles, and three book chapters.

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.

Contact:

Maureen Cochran

610-861-4701

mcochran@particlesciences.com


'/>"/>
SOURCE Particle Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Chairman Robert Essner Announces June 27 Retirement
2. Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems
3. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
4. Hiemstra Appoints Robert C. Glines as Director of Business Development
5. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
6. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
7. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
8. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
9. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
10. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
11. Immunotec Inc. announces retirement of President & CEO C.H. (Chuck) Roberts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
Breaking Biology Technology:
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):